Bookbuilding IPO | ₹[.] Cr | Listing at NSE SME |
Avience Biomedicals Ltd. IPO is a Book Build Issue consisting solely of fresh issue of upto 0.16 crore equity shares.
The equity shares are proposed to be listed on the NSE SME. Fintellectual Corporate Advisors Pvt.Ltd. is the book running lead manager and Skyline Financial Services Pvt.Ltd. is the registrar of the issue. Key details like IPO dates, IPO price bands and lot size are yet to be announced.
Refer to Avience Biomedicals IPO DRHP for more details.
| IPO Date | [.] |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Price Band | |
| Lot Size | |
| Sale Type | Fresh capital only |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Total Issue Size | 16,08,000 shares (agg. up to ₹[.] Cr) |
| Reserved for Market Maker | 80,400 shares Asnani Stock Broker Pvt.Ltd. (agg. up to ₹[.] Cr) |
| Fresh Issue (Ex Market Maker) | 15,27,600 shares (agg. up to ₹[.] Cr) |
| Net Offered to Public | 15,27,600 shares (agg. up to ₹[.] Cr) |
| Share Holding Pre Issue | 40,31,256 shares |
| Share Holding Post Issue | 56,39,256 shares |
| Description | Date |
|---|---|
| Filed with SEBI/Exchange | Fri, Dec 27, 2024 |
| Offer document withdrawn | Thu, May 8, 2025 |
| Filed with SEBI/Exchange | Wed, Jul 23, 2025 |
| SEBI/Exchange approval received | Fri, Aug 1, 2025 |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 50.00% of the Net Issue |
| Retail Shares Offered | Not less than 35.00% of the Net Issue |
| NII Shares Offered | Not more than 15% of the Net Issue |
Incorporated in June 2024, Avience Biomedicals Limited is an ISO certified company specializing in manufacturing, supplying, and exporting molecular diagnostic solutions, focusing on biotechnology, genomics, and the IVD industry.
Avience Biomedicals Limited has expanded its product range from IVD rapid test kits to a comprehensive line of medical devices, including serology products and biochemistry analyzers. This demonstrates a commitment to diverse healthcare needs, focusing exclusively on the B2B and B2G markets.
The company's products cater to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide as well as overseas.
In addition to manufacturing, the Company also act as distributors and traders of medical equipment.
The company's manufacturing unit is situated in Noida, Uttar Pradesh.
The company offers a comprehensive range of diagnostic solutions, including:
As of December 2024, the company had 65 permanent employees and 33 contractual employees
Competitive Strength
Avience Biomedicals Ltd.'s revenue increased by 89% and profit after tax (PAT) rose by 239% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|
| Assets | 56.52 | 34.65 |
| Total Income | 45.97 | 24.37 |
| Profit After Tax | 7.29 | 2.15 |
| EBITDA | 11.41 | 4.08 |
| NET Worth | 22.85 | 6.23 |
| Reserves and Surplus | 18.82 | 2.94 |
| Total Borrowing | 22,15,820.00 | 15.13 |
| Amount in ₹ Crore | ||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Part finances the capital expenditure towards setting up of a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh | 16.88 |
| 2 | Funding the working capital requirement of the company | 11.00 |
| 3 | General Corporate Purposes |
| KPI | Mar 31, 2025 |
|---|---|
| ROE | 50.14% |
| ROCE | 24.84% |
| Debt/Equity | 0.97 |
| RoNW | 50.14% |
| PAT Margin | 15.86% |
| EBITDA Margin | 25.22% |
| Pre IPO | Post IPO | |
|---|---|---|
| Promoter Holding | 92.85% | 66.37% |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Book Running Lead Managers fees including underwriting fees | |
| 2 | Fees Payable to Registrar to the Issue | |
| 3 | Fees Payable Advertising, Marketing Expenses and Printing Expenses | |
| 4 | Fees Payable to Regulators including Stock Exchanges and other Intermediaries | |
| 5 | Fees Payable to Statutory Auditors, Legal Advisors and Other Professionals | |
| 6 | Fees Payable to Market Maker (for Three Years) | |
| 7 | Payment for Printing & Stationery, Postage, etc. | |
| 8 | Escrow Bank Fees | |
| 9 | Other (Brokerage and Selling Commission, Banker to the Issue etc.) |
Lead Manager Reports
Avience Biomedicals IPO is a SME IPO of 16,08,000 equity shares of the face value of ₹10 aggregating up to ₹[.] Crores. The issue is priced at To be declared. The minimum order quantity is .
The Avience Biomedicals IPO open and close dates are not available as of now.
Skyline Financial Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Avience Biomedicals IPO using UPI as a payment gateway. Zerodha customers can apply in Avience Biomedicals IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Avience Biomedicals IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Avience Biomedicals IPO dates are not announced. Please check back again after some time.
Avience Biomedicals IPO lot size and the minimum order quantity is not available at this time. Please check again later.
You can apply in Avience Biomedicals IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Avience Biomedicals IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Avience Biomedicals IPO allotment status.
The Avience Biomedicals IPO listing date is not yet announced. The tentative date of listing is .
